Investigational Drug Information for Fosbretabulin
✉ Email this page to a colleague
What is the drug development status for Fosbretabulin?
Fosbretabulin is an investigational drug.
There have been 18 clinical trials for Fosbretabulin.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2015.
The most common disease conditions in clinical trials are Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic, and Ovarian Neoplasms. The leading clinical trial sponsors are Mateon Therapeutics, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.
There are three hundred and thirty-three US patents protecting this investigational drug and two international patents.
Summary for Fosbretabulin
| US Patents | 333 |
| International Patents | 2,502 |
| US Patent Applications | 1,086 |
| WIPO Patent Applications | 566 |
| Japanese Patent Applications | 172 |
| Clinical Trial Progress | Phase 2 (2015-03-01) |
| Vendors | 29 |
Recent Clinical Trials for Fosbretabulin
| Title | Sponsor | Phase |
|---|---|---|
| Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression | Lowell Anthony, MD | Phase 1 |
| FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer | Mateon Therapeutics | Phase 2/Phase 3 |
| Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer | Mateon Therapeutics | Phase 3 |
Clinical Trial Summary for Fosbretabulin
Top disease conditions for Fosbretabulin
Top clinical trial sponsors for Fosbretabulin
US Patents for Fosbretabulin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Fosbretabulin | ⤷ Try a Trial | Pharmaceutical compositions | Momenta Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Try a Trial |
| Fosbretabulin | ⤷ Try a Trial | Small molecule drug conjugates | Eth Zurich (Zurich, CH) | ⤷ Try a Trial |
| Fosbretabulin | ⤷ Try a Trial | Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer | XAVIER UNIVERSITY OF LOUSIANA (New Orleans, LA) | ⤷ Try a Trial |
| Fosbretabulin | ⤷ Try a Trial | Heteroaryl compounds as IRAK inhibitors and uses thereof | Merck Patent GmbH (Darmstadt, DE) | ⤷ Try a Trial |
| Fosbretabulin | ⤷ Try a Trial | Methods and devices for cellular transplantation | Sernova Corporation (London, Ontario, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Fosbretabulin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Fosbretabulin | Australia | AU2014274377 | 2033-05-28 | ⤷ Try a Trial |
| Fosbretabulin | Canada | CA2910837 | 2033-05-28 | ⤷ Try a Trial |
| Fosbretabulin | European Patent Office | EP3003324 | 2033-05-28 | ⤷ Try a Trial |
| Fosbretabulin | Japan | JP2016520613 | 2033-05-28 | ⤷ Try a Trial |
| Fosbretabulin | World Intellectual Property Organization (WIPO) | WO2014193818 | 2033-05-28 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
